Latest News - Baxter
Top Corporates Hub
Baxter
Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading
20.02.2026 10:12
Key market opportunities in the fill finish manufacturing sector include rising demand for cell and gene therapies, expansion in personalized medicine production, and increased outsourcing to CMOs. Growth is driven by innovations in aseptic filling technologies, automated systems, and a focus on regulatory compliance. Fill Finish Manufacturing Market Fill Finish Manufacturing Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The "Fill Finish Manufacturing Market Report 2026" has been added to Res
Pale Fire Capital Bets Big on Healthcare With a 2.07 Million Share Baxter International (BAX) Investment
16.02.2026 18:08
This global healthcare firm provides essential medical devices and therapies to hospitals and care facilities in over 100 countries.
Baxter’s New Decentralized Model Tests Earnings And Valuation Expectations
16.02.2026 17:12
Baxter International (NYSE:BAX) has announced a major organizational transformation with a new decentralized operating model. The company is also adjusting its board structure following mixed Q4 2025 results and ongoing operational challenges. The changes are part of a broader effort to address earnings underperformance, margin pressures, and efficiency efforts. Baxter International, a global medical products and therapies company, is reshaping how its business is run by pushing more...
Clinical Communication & Collaboration Market by Platform, Component, Application, End User - Global Forecast to 2030 with Cisco Systems, Oracle, Baxter, Avaya, Spok Leading
16.02.2026 15:41
The global clinical communication and collaboration market is set to reach $5.31 billion by 2030, growing at a CAGR of 13.02%. This growth is fueled by the increasing need for real-time communication, care coordination, and workflow efficiency in healthcare. A surge in mobile, cloud-based platform adoption and a shift to integrated, secure communication drives this expansion. Case studies from Stryker, Imprivata, and Ascom reveal notable improvements in staff responsiveness, patient admission ti
1 Mid-Cap Stock Worth Investigating and 2 We Brush Off
16.02.2026 04:37
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Baxter (BAX) Q4 Earnings: What To Expect
11.02.2026 03:03
Healthcare company Baxter International (NYSE:BAX) will be reporting earnings this Thursday before market open. Here’s what investors should know.
Seeking Clues to Baxter (BAX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
10.02.2026 14:15
Beyond analysts' top-and-bottom-line estimates for Baxter (BAX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Baxter cuts roughly 90 jobs at IV solutions plant that recovered from Hurricane Helene
10.02.2026 10:54
Hospital demand for IV solutions in the U.S. is lower than before Hurricane Helene, the company said.
Here’s What Hit Baxter (BAX) in Q4
03.02.2026 12:49
Pzena Investment Management recently released its fourth-quarter 2025 commentary for “Pzena Focused Value Strategy.” A copy of the letter can be downloaded here. The fourth quarter was defined by strong AI momentum and continued market dominance by mega-cap stocks. In this environment, Pzena Focused Value Strategy underperformed the Russell 1000® Value Index, delivering a net return of […]
Does Baxter International (BAX) Offer Opportunity After Prolonged Share Price Weakness?
01.02.2026 19:04
If you are wondering whether Baxter International's share price still reflects its underlying business, the key question is whether the stock now offers value or just looks cheap on the surface. The stock recently closed at US$20.07, with returns of 1.2% over 7 days and 2.9% over 30 days. However, over the longer term it shows a 37.2% decline over 1 year, 53.6% over 3 years and 71.1% over 5 years, which raises very different questions about risk and opportunity. Recent coverage around Baxter...
MediPharm Labs CEO David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
19.01.2026 14:56
MediPharm Labs (LABS.TO) on Monday announced that David Pidduck will be stepping down from his role
What You Need To Know Ahead of Baxter International's Earnings Release
19.01.2026 11:59
Baxter International is set to announce its fourth-quarter results soon, with analysts predicting a single-digit decline in the company's earnings.
Baxter Introduces the Dynamo Series, a New Smart Stretcher to Help Address Common Challenges in Hospital Settings
13.01.2026 14:00
DEERFIELD, Ill., January 13, 2026--BAXTER INTRODUCES THE DYNAMO SERIES, A NEW SMART STRETCHER TO HELP ADDRESS COMMON CHALLENGES IN HOSPITAL SETTINGS
Does Baxter International (BAX) Now Look Fairly Priced After Multi‑Year Share Price Slide
13.01.2026 05:11
If you are wondering whether Baxter International's current share price reflects its underlying worth, this article is designed to help you break that question down clearly. The stock most recently closed at US$20.15, with returns of 1.3% over the past week, 5.2% over the past month, 3.3% year to date, but a 32.7% decline over one year, 51.5% decline over three years, and 72.0% decline over five years. These share price moves sit against a backdrop of ongoing attention on Baxter...
MUSC Health and Baxter Announce Strategic Partnership to Transform Bedside Care Delivery and Address Critical Nursing Challenges
08.01.2026 14:00
CHARLESTON, S.C., January 08, 2026--MUSC Health and Baxter International Inc. (NYSE:BAX), a global medtech leader, are entering into a multi-year strategic partnership that aims to enhance the high-quality and safe patient care already delivered at MUSC Health, MUSC’s health care system, through integrated connected care technologies.
Artisan Mid Cap Value Fund’s Views on Baxter International (BAX)
05.01.2026 12:19
Artisan Partners, an investment management company, released its “Artisan Mid Cap Value Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the quarter, the fund’s Investor Class fund ARTQX returned 0.97%, Advisor Class fund APDQX posted a return of 0.98%, and Institutional Class fund APHQX returned 0.97%, compared to […]
Assessing Baxter International (BAX) Valuation After Recent Share Price Momentum And Margin Concerns
05.01.2026 10:08
Baxter International (BAX) has drawn fresh investor attention after recent trading, with the share price at $19.50 and mixed returns over the month and past 3 months prompting closer scrutiny of its fundamentals. See our latest analysis for Baxter International. The recent 1 day share price return of 2.04% and 1 month share price return of 5.18% sit against a 1 year total shareholder return decline of 33.07%. This indicates that short term momentum is improving, while longer term performance...
BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care
15.12.2025 15:24
Baxter shows EMR-integrated smart pumps cut safety alerts and speed IV setup, backed by real-world data from over a million infusions at ASHP 2025.
Baxter International Stock: Is BAX Underperforming the Health Care Sector?
12.12.2025 08:49
Baxter International has lagged the broader health care sector by a wide margin over the past year, and analysts are taking a guarded stance on its outlook.
Is Baxter International Offering Long Term Value After Years of Share Price Declines?
12.12.2025 00:14
Wondering if Baxter International is a beaten down healthcare name or a genuine value opportunity at today’s price? Let’s unpack what the market might be missing. The stock has inched up 2.3% over the last week and 3.6% over the past month, but that is against a much steeper backdrop with returns of -35.4% year to date and a -74.0% slide over five years. Investors have been reacting to Baxter’s ongoing portfolio reshaping, including moves to streamline its medical products business and...